Eculizumab in Primary MPGN

NCT02093533 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Membranoproliferative Glomerulonephritis

Interventions

DRUG: Eculizumab

Sponsor

Mario Negri Institute for Pharmacological Research

Collaborators

[object Object]